Out of 32 hopefuls, just nine investigational products targeting unmet medical needs earned a coveted spot on the European Medicines Agency’s PRIME (priority medicines) scheme in the first half of 2024.
EMA’s PRIME Sees New Targets, More Approvals But Few Fast-Track Reviews
Nine new entries targeting a wide range of unmet medical needs. Several EU marketing approvals and two withdrawals. And an accelerated assessment tool that was seldom used. These were among the activities noted as part of the European Medicines Agency’s priority medicines scheme during the first half of 2024.
